118 related articles for article (PubMed ID: 28365509)
1. Myristic acid-modified thymopentin for enhanced plasma stability and immune-modulating activity.
Tan Y; Wang W; Wu C; Pan Z; Yao G; Fang L; Su W
Int Immunopharmacol; 2017 Jun; 47():88-94. PubMed ID: 28365509
[TBL] [Abstract][Full Text] [Related]
2. Targeting the TLR2 Receptor With a Novel Thymopentin-Derived Peptide Modulates Immune Responses.
Wei X; Zhang L; Zhang R; Wu R; Petitte JN; Hou Y; Si D; Ahmad B; Guo H; Zhang M; Cheng Q; Tong Y
Front Immunol; 2021; 12():620494. PubMed ID: 34122400
[TBL] [Abstract][Full Text] [Related]
3. Thymopentin nanoparticles engineered with high loading efficiency, improved pharmacokinetic properties, and enhanced immunostimulating effect using soybean phospholipid and PHBHHx polymer.
Wu C; Zhang M; Zhang Z; Wan KW; Ahmed W; Phoenix DA; Elhissi AM; Sun X
Mol Pharm; 2014 Oct; 11(10):3371-7. PubMed ID: 24641274
[TBL] [Abstract][Full Text] [Related]
4. Novel strategy for immunomodulation: Dissolving microneedle array encapsulating thymopentin fabricated by modified two-step molding technology.
Lin S; Cai B; Quan G; Peng T; Yao G; Zhu C; Wu Q; Ran H; Pan X; Wu C
Eur J Pharm Biopharm; 2018 Jan; 122():104-112. PubMed ID: 29042238
[TBL] [Abstract][Full Text] [Related]
5. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles.
Li YZ; Sun X; Gong T; Liu J; Zuo J; Zhang ZR
Pharm Res; 2010 Sep; 27(9):1977-86. PubMed ID: 20625801
[TBL] [Abstract][Full Text] [Related]
6. Influence of potential inhalation carriers on stability of thymopentin in rat bronchoalveolar lavage fluid.
Cai C; Wang L; Dong W; Tang X
Drug Deliv; 2014 Sep; 21(6):495-500. PubMed ID: 24611940
[TBL] [Abstract][Full Text] [Related]
7. Box-Behnken optimization design and enhanced oral bioavailability of thymopentin-loaded poly (butyl cyanoacrylate) nanoparticles.
Jin X; Huang A; Ping Q; Cao F; Su Z
Pharmazie; 2011 May; 66(5):339-47. PubMed ID: 21699067
[TBL] [Abstract][Full Text] [Related]
8. [Research on thymopentin-loaded N-trimethyl chitosan nanoparticles administered through mouth].
Tang SW; Yuan XJ; Zhang ZR; Song QG; He Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):885-8. PubMed ID: 17953385
[TBL] [Abstract][Full Text] [Related]
9. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin.
Yin Y; Chen D; Qiao M; Lu Z; Hu H
J Control Release; 2006 Dec; 116(3):337-45. PubMed ID: 17097180
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization and in vivo pharmacodynamic evaluation of thymopentin loaded poly(lactide acid)/poly(lactide-co-glycolide acid) implants.
Wei G; Jin L; Xu L; Liu Y; Lu W
Int J Pharm; 2010 Oct; 398(1-2):123-9. PubMed ID: 20674730
[TBL] [Abstract][Full Text] [Related]
11. Thymopentin-loaded pH-sensitive chitosan nanoparticles for oral administration: preparation, characterization, and pharmacodynamics.
Zheng AP; Wang JC; Lu WL; Zhang X; Zhang H; Wang XQ; Zhang Q
J Nanosci Nanotechnol; 2006; 6(9-10):2936-44. PubMed ID: 17048501
[TBL] [Abstract][Full Text] [Related]
12. Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin.
He W; Jiang X; Zhang ZR
J Pharm Sci; 2008 Jun; 97(6):2250-9. PubMed ID: 17853430
[TBL] [Abstract][Full Text] [Related]
13. Novel thymopentin release systems prepared from bioresorbable PLA-PEG-PLA hydrogels.
Zhang Y; Wu X; Han Y; Mo F; Duan Y; Li S
Int J Pharm; 2010 Feb; 386(1-2):15-22. PubMed ID: 19895878
[TBL] [Abstract][Full Text] [Related]
14. [Mediation of cellular immune response by TP5 in pathogenesis of myasthenia gravis].
He XT; Liu WB; Zhang Y; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(47):3337-40. PubMed ID: 20193562
[TBL] [Abstract][Full Text] [Related]
15. Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies.
Zhang T; Qin XY; Cao X; Li WH; Gong T; Zhang ZR
Acta Pharmacol Sin; 2019 Apr; 40(4):514-521. PubMed ID: 30002492
[TBL] [Abstract][Full Text] [Related]
16. Increased antitumor activity of tumor-specific peptide modified thymopentin.
Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
[TBL] [Abstract][Full Text] [Related]
17. The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin.
Gallo F; Morale MC; Sambataro D; Farinella Z; Scapagnini U; Marchetti B
Breast Cancer Res Treat; 1993 Sep; 27(3):221-37. PubMed ID: 8312580
[TBL] [Abstract][Full Text] [Related]
18. [A clinico-epidemiological study on the efficacy of thymopentin therapy in patients with chronic bronchitis and cellular immunity deficiency].
Amoroso A; Di Rosa R; Guidotti G; Ferri GM; Afeltra A
Recenti Prog Med; 1990 Jan; 81(1):29-32. PubMed ID: 2236822
[TBL] [Abstract][Full Text] [Related]
19. Vesicular phospholipid gels using low concentrations of phospholipids for the sustained release of thymopentin: pharmacokinetics and pharmacodynamics.
Zhong Y; Chen L; Zhang Y; Li W; Sun X; Gong T; Zhang Z
Pharmazie; 2013 Oct; 68(10):811-5. PubMed ID: 24273885
[TBL] [Abstract][Full Text] [Related]
20. Multivesicular liposomes for the sustained release of thymopentin: stability, pharmacokinetics and pharmacodynamics.
Zuo J; Gong T; Sun X; Huang Y; Peng Q; Zhang Z
Pharmazie; 2012 Jun; 67(6):507-12. PubMed ID: 22822538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
